Context. - Observational studies have found lower rates of coronary heart disease (CHD) in postmenopausal women who take estrogen than in women who do not, but this potential benefit has not been confirmed in clinical trials.
- To determine if estrogen plus progestin therapy alters the risk for CHD events in postmenopausal women with established coronary disease.
- Randomized, blinded, placebo-controlled secondary prevention trial.
- Outpatient and community settings at 20 US clinical centers.
- A total of 2763 women with coronary disease, younger than 80 years, and postmenopausal with an intact uterus.
Mean age was 66.7 years.
- Either 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate in 1 tablet daily (n=1380) or a placebo of identical appearance (n=1383).
Follow-up averaged 4.1 years ; 82% of those assigned to hormone treatment were taking it at the end of 1 year, and 75% at the end of 3 years.
- The primary outcome was the occurrence of non-fatal myocardial infarction (MI) or CHD death.
Secondary cardiovascular outcomes included coronary revascularization, unstable angina, congestive heart failure, resuscitated cardiac arrest, stroke or transient ischemic attack, and peripheral arterial disease.
All-cause mortality was also considered.
Mots-clés Pascal : Cardiopathie coronaire, Association, Postménopause, Oestrogène, Chimiothérapie, Randomisation, Progestérone, Essai thérapeutique contrôlé, Placebo, Prévention, Secondaire, Femelle, Traitement, Homme, Appareil circulatoire pathologie, Hormone stéroïde sexuelle
Mots-clés Pascal anglais : Coronary heart disease, Association, Postmenopause, Estrogen, Chemotherapy, Randomization, Progesterone, Controlled therapeutic trial, Placebo, Prevention, Secondary, Female, Treatment, Human, Cardiovascular disease, Sex steroid hormone
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0418531
Code Inist : 002B02O. Création : 25/01/1999.